Jordi labs — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Jordi Labs is a specialized contract research organization (CRO) providing advanced analytical chemistry services and consulting. Its core business revolves around material characterization, failure analysis, and regulatory testing support for highly regulated industries like medical devices and pharmaceuticals, with a strong niche in E&L studies. Recently acquired by RQM+, a larger life sciences consulting firm, Jordi Labs leverages its four decades of expertise to solve complex chemical analysis problems for clients globally. The company also manufactures and sells proprietary HPLC columns, adding a product-based revenue stream to its service model.

Diagnostics

Technology Platform

Advanced analytical chemistry techniques and proprietary methodologies for material characterization, including specialized Extractables & Leachables (E&L) testing and polymer analysis. Also manufactures proprietary HPLC columns for liquid chromatography.

Opportunities

The acquisition by RQM+ provides immediate access to a vast client base in the medical device industry, enabling integrated regulatory and analytical service offerings.

Growing regulatory complexity and outsourcing trends in pharma, medtech, and consumer goods sectors drive sustained demand for specialized analytical testing and expert consulting services.

Risk Factors

Revenue is heavily dependent on regulatory-driven testing requirements, which could be impacted by changes in guidelines or industry submission cycles.

Successful integration into the larger RQM+ organization is critical to realize synergies and avoid operational or cultural disruption that could affect service quality.

Competitive Landscape

Jordi Labs competes in the analytical CRO space against large global players (e.g., Eurofins, SGS, Element) and numerous specialized independent labs. Its differentiation lies in deep niche expertise (especially in E&L), Ph.D.-led consulting, and its unique dual model of services plus proprietary column products. The RQM+ acquisition creates a distinct competitive advantage through vertical integration.

More companies in Diagnostics & Precision Medicine →More companies in United States →